Actionable only as a high-risk speculative catalyst watch — the upcoming CannEpil® FDA submission and any financing announcement will determine near-term direction. A $2M market cap micro-cap with no revenue and no financial disclosures in this filing; traders should closely monitor for material dilution from the planned financing and for FDA submission outcomes. This is a binary event-driven play, not a fundamental re-rating.
Price Chart
Executive Summary
Endovia Health Sciences issued a press release on August 31, 2026 welcoming the federal government's support for rescheduling marijuana from Schedule I to Schedule III, and expects to submit a CannEpil® Z submission to the FDA in the coming week and request a pre-submission conference. The filing contains no financial data, no revenue figures, no reported earnings, and no guidance — it is a purely forward-looking policy commentary and pipeline update for a $2M market cap, pre-revenue cannabinoid company.
Key Facts
- Company supports federal shift to Schedule III for marijuana; views it as a positive regulatory evolution for cannabinoid-based medicines.
- Expects to submit CannEpil® Z submission to FDA 'in the coming week' and request a pre-submission conference.
- Actively reviewing additional cannabinoid formulations and IP for licensing, acquisition, or collaboration.
- Working with capital partners to finalize expanded financing — amount and terms undisclosed.
- Company rebranded from SPLASH BEVERAGE GROUP to Endovia Health Sciences on August 24, 2026; ticker changed to EDVA.
- Market cap is approximately $2M — tiny base, pre-revenue, no financial data provided in this filing.
Financial Impact
No financial figures reported in this filing. Financing being finalized with undisclosed terms.
Risk Factors
- No financial data or revenue reported — company is pre-revenue and speculative.
- Financing being finalized — terms and dilution amount unknown but potentially significant for a $2M market cap issuer.
- FDA submission is a regulatory step with uncertain outcome; no guarantee of approval or timely review.
- Schedule III rescheduling is a federal administrative process that remains uncertain and may take years to finalize.
- Tiny market cap micro-cap — extreme volatility, limited liquidity, and high risk of capital loss.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-001173 |
| Document: e7903_ex99-1.htm | 0001731122-26-001173 |
| Document: 0001731122-26-001173-index-headers.html | 0001731122-26-001173 |
| Document: 0001731122-26-001173-index.html | 0001731122-26-001173 |
| Document: 0001731122-26-001173.txt | 0001731122-26-001173 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13G | $0.1600 $0.1577 | ▼ −1.44% | ▼ −2.15% | $0.1600 (−0.00%) |
Oct 15, 2026 11d ago | 8-K | $0.1460 $0.1350 | ▲ +7.53% | ▲ +7.96% | $0.1600 (−9.59%) |
Oct 6, 2026 20d ago | 8-K | $0.1650 $0.1599 | ▲ +3.09% | ▲ +2.67% | $0.1600 (+3.03%) |
Oct 5, 2026 21d ago | DEF 14A | $0.1679 $0.1650 | ▲ +1.73% | ▲ +1.49% | $0.1600 (+4.71%) |
Oct 5, 2026 21d ago | 8-K | $0.1680 $0.1650 | ▼ −1.79% | ▼ −1.55% | $0.1600 (−4.76%) |
Aug 31, 2026 8w ago | 8-K | $0.2954 $0.2614 | ▼ −11.51% | ▼ −11.95% | $0.1600 (−45.84%) |
Aug 25, 2026 8w ago | EFFECT | $0.4182 $0.3650 | ▲ +12.72% | ▲ +12.74% | $0.1600 (+61.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers